INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 24, 2021 |
Director, President and Chief Scientific
Trans History: 617
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 211,585 | -- | -- |
| May 19, 2021 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Bona fide gift | 41,178 | -- | -- |
| May 14, 2021 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 12,500 | -- | -- |
| Apr 15, 2021 |
Director, President and Chief Scientific
Trans History: 617
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 14,000 | -- | -- |
| Apr 15, 2021 |
Director, President and Chief Scientific
Trans History: 617
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 5,383 | -- | -- |
| Feb 23, 2021 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | -- | -- |
| Feb 23, 2021 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 248,079 | -- | -- |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 617
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- | -- |
| Nov 16, 2020 |
EVP Research
Trans History: 222
|
EVP Research | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 13,736 | -- | -- |
| Oct 22, 2020 |
EVP Research
Trans History: 222
|
EVP Research | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,264 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.